3 results
PrimaryObjectives: 1. Evaluate the efficacy of adding anacetrapib 100 mg for 52 weeks relative to placebo on plasma concentrations of LDL-C. 2. Evaluate the safety and tolerability of 52 weeks of treatment with anacetrapib 100 mg.Hypotheses: 1.…
The primary objective of the study is to evaluate the efficacy of agomelatine (25-50 mg/day) compared to placebo on the reduction of Obsessive and Compulsive symptoms by using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) after 16 weeks of…
Primary Objective* To assess the safety, tolerability, and efficacy (in terms of change in DAS28 [using C-ReactiveProtein (CRP)] from baseline) of JNJ-38518168 at a dose of 100 mg/day for up to 12 weekscompared to placebo in subjects with active…